Bruker (NASDAQ:BRKR) Stock Price Breaks Above 50-Day Moving Average - Here's What Happened

Key Points

• Bruker shares rose above their 50-day moving average, trading as high as $68.98 and last at $63.79.
• Q3 adjusted EPS of $0.56 and revenue of $874 million both exceeded analyst estimates; revenue increased 1.6% year over year.
• Management cited stronger bookings, margin expansion, and returning U.S. academic demand, while its 2026 revenue outlook midpoint was slightly below consensus.

Bruker Corporation (NASDAQ:BRKR - Get Free Report)'s share price passed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $58.95 and traded as high as $68.98. Bruker shares last traded at $63.79, with a volume of 7,408,425 shares trading hands.

Key Bruker News

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker reported Q3 adjusted earnings of $0.56 per share, versus the $0.42 consensus estimate, and revenue of $874 million, above the $865 million estimate. Revenue grew 1.6% year over year. Bruker Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management highlighted margin expansion, strong bookings, and a return of U.S. academic demand. The company also sees potential for double-digit EPS growth in fiscal 2027, supporting optimism about future performance. Bruker sees US academic demand return in Q3, targets double-digit EPS growth in FY27
• Neutral Sentiment: Bruker forecast 2026 revenue of $3.52 billion–$3.56 billion, with non-GAAP EPS of $2.10–$2.15. The EPS range brackets the $2.12 analyst estimate, while the revenue midpoint is slightly below the $3.56 billion consensus. Bruker 2026 revenue outlook
• Negative Sentiment: Coverage also flagged a substantial goodwill charge, which could weigh on reported results and temper the positive read-through from stronger margins and adjusted earnings. Bruker Q3 2026: Margin Surge Masks a Steep Goodwill Charge

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. TD Cowen raised their target price on Bruker from $60.00 to $62.00 and gave the stock a "hold" rating in a research report on Tuesday, October 13th. Zacks Research downgraded Bruker from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 2nd. Guggenheim increased their price target on shares of Bruker from $70.00 to $72.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Weiss Ratings reissued a "sell (d+)" rating on shares of Bruker in a report on Monday, August 31st. Finally, Leerink Partners raised their price objective on shares of Bruker from $60.00 to $80.00 and gave the stock an "outperform" rating in a report on Tuesday, September 29th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bruker currently has an average rating of "Moderate Buy" and an average price target of $59.43.

Bruker Stock Up 12.9%

The firm's 50 day simple moving average is $58.95 and its 200-day simple moving average is $50.48. The company has a market cap of $9.72 billion, a price-to-earnings ratio of -91.13, a P/E/G ratio of 1.73 and a beta of 1.26. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.42 by $0.14. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The business had revenue of $874.00 million for the quarter, compared to analysts' expectations of $865.16 million. During the same quarter in the previous year, the firm earned $0.45 earnings per share. The business's revenue was up 1.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Monday, September 21st were given a $0.05 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker's dividend payout ratio is -28.57%.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total transaction of $105,740.00. Following the transaction, the vice president owned 134,806 shares of the company's stock, valued at $7,127,193.22. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 27.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bruker

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Global Retirement Partners LLC acquired a new position in Bruker in the 2nd quarter valued at about $38,000. Provenance Wealth Advisors LLC acquired a new stake in Bruker during the 3rd quarter worth approximately $52,000. Root Financial Partners LLC acquired a new stake in Bruker during the 3rd quarter worth approximately $57,000. Essential Partners LLC acquired a new stake in Bruker during the 1st quarter worth approximately $36,000. Finally, FNY Investment Advisers LLC purchased a new position in shares of Bruker in the 2nd quarter valued at approximately $60,000. Hedge funds and other institutional investors own 79.52% of the company's stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company's product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.